How should terlipressin be administered in patients with hepatorenal syndrome-associated acute kidney injury (HRS‑AKI)?

Terlipressin Administration in HRS-AKI

Initiate terlipressin as 1 mg IV bolus every 4-6 hours (total 4-6 mg/day) through a peripheral line without requiring ICU monitoring, and increase to 2 mg every 4-6 hours (total 8-12 mg/day) if serum creatinine fails to decrease by at least 25% by day 3. 1

Dosing Regimens

Standard Bolus Dosing (FDA-Approved)

• Initial dose: 1 mg IV bolus every 6 hours (4 mg/day total) 1
• Dose escalation: Increase to 2 mg every 6 hours (8 mg/day total) on day 4 if creatinine reduction is <30% 1
• Alternative escalation: Increase to 2 mg every 4-6 hours (8-12 mg/day total) if creatinine fails to decrease by ≥25% at day 3 1
• Administration route: Peripheral IV line—no central line required 1

Continuous Infusion Alternative

• Starting dose: 2 mg/day as continuous IV infusion 1
• Titration: Increase gradually every 24-48 hours up to maximum 12 mg/day 1
• Advantage: Lower rates of ischemic complications with similar efficacy compared to bolus dosing 1
• Note: Continuous infusion is not FDA-approved in the United States but is commonly used internationally 1

Treatment Duration and Discontinuation

• Maximum duration: Up to 14 days 1
• Discontinuation criteria: Stop 24 hours after serum creatinine decreases to <1.5 mg/dL 1 or returns to within ≤0.3 mg/dL of baseline for 2 consecutive days 1
• Early initiation: Start treatment when creatinine remains >2× baseline despite volume resuscitation with albumin 1

Concurrent Albumin Administration

Initial Loading

• Day 1: 1 g/kg IV albumin 1
• Maintenance: 20-40 g/day during terlipressin treatment 1

Duration Considerations

• The rationale for albumin is to enhance splanchnic vasoconstriction effects, likely achieved after 1-2 days 1
• Critical monitoring: Assess volume status carefully to avoid pulmonary edema, using point-of-care ultrasonography when available 1
• Caution: Fluid status requires close monitoring due to risk of pulmonary edema with excessive albumin 1

Monitoring Requirements

No ICU Required

• Terlipressin does not require ICU-level monitoring 1
• Can be administered on general medical floors with appropriate monitoring 1

Essential Monitoring Parameters

• Vital signs: Blood pressure and heart rate (expect MAP increase of ~16 mmHg and heart rate decrease of ~11 bpm within 1-2 hours) 2
• Renal function: Daily serum creatinine to assess response 1
• Volume status: Urine output, clinical examination, echocardiography or CVP if central line present 1
• Ischemic complications: Monitor for angina, peripheral ischemia, skin ischemia, intestinal ischemia 1

Absolute Contraindications

Do Not Use Terlipressin If:

• Serum creatinine ≥5 mg/dL (low response rates, unlikely to benefit) 1
• Oxygen saturation <90% (FDA restriction) 1
• Active ischemia: Ongoing coronary, peripheral, or mesenteric ischemia 1
• ACLF grade 3: Use with extreme caution as benefits may not outweigh risks 1

Patient Selection Criteria

Optimal Candidates

• Creatinine threshold: Start early when creatinine 2.25-5 mg/dL (higher levels associated with lower response) 1
• ACLF grade: Patients without ACLF grade 3 or with early-stage ACLF have better benefit-to-risk profile 1
• Volume status: After adequate volume resuscitation with albumin (1 g/kg/day for 2 days) 1

Expected Response Rates

• HRS reversal: Approximately 40-43% with terlipressin versus 17% with placebo 1, 3
• Predictors of non-response: Baseline creatinine >5 mg/dL, presence of acute tubular necrosis, cirrhotic cardiomyopathy with E/e' >12.5 1, 4, 5

Common Pitfalls to Avoid

Ischemic Complications

• Incidence: Occur in approximately 20-21% of patients 1, 6
• Prevention strategy: Start at lowest dose and titrate gradually upward 1
• High-risk scenario: Patients who develop adverse events have significantly worse prognosis (only 1/3 alive at day 90) 7

Respiratory Failure Risk

• Overall incidence: 11-20% of patients 4, 8
• Key predictor: Presence of pneumonia (OR 7.80), not albumin amount or ACLF grade 4
• Risk mitigation: Exclude patients with baseline hypoxemia (<90% oxygen saturation) 1
• Volume management: Carefully assess need for continued albumin beyond initial 1-2 days 1

Inappropriate Use

• ATN patients: Response rate only 29% compared to 51% in HRS-AKI; risks may outweigh benefits 4
• Verification needed: Ensure diagnosis is truly HRS-AKI, not other AKI phenotypes (hypovolemic, ATN) 4
• Real-world data: Terlipressin is frequently used outside its primary indication with lower efficacy 4

Pharmacodynamic Considerations

• Onset of action: Blood pressure effects evident within 5 minutes, maintained for ≥6 hours 2
• Peak effect: Maximum MAP increase occurs at 1.2-2 hours post-dose 2
• Mechanism: Increases renal blood flow by reducing splanchnic vasodilation and portal hypertension 2
• MAP target: Each 5 mmHg increase in MAP associated with 1.17× hazard of HRS-AKI reversal 9